A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses

Tools

Gomez-Roman, Natividad and Stevenson, Katrina and Gilmour, Lesley and Hamilton, Graham and Chalmers, Anthony J (2017) A novel 3D human glioblastoma cell culture system for modeling drug and radiation responses. Neuro-Oncology, 19 (2). pp. 229-241. ISSN 1522-8517 (https://doi.org/10.1093/neuonc/now164)

[thumbnail of Gomez-Roman-etal-NO-2016-A-novel-3D-human-glioblastoma-cell-culture-system]
Preview
 Text. Filename: Gomez_Roman_etal_NO_2016_A_novel_3D_human_glioblastoma_cell_culture_system.pdf
Final Published Version
License: Creative Commons Attribution-NonCommercial 4.0 logo
Download (1MB)| Preview

Abstract

Background: Glioblastoma (GBM) is the most common primary brain tumor, with dismal prognosis. The failure of drug-radiation combinations with promising preclinical data to translate into effective clinical treatments may relate to the use of simplified 2-dimensional in vitro GBM cultures. Methods: We developed a customized 3D GBM culture system based on a polystyrene scaffold (Alvetex) that recapitulates key histological features of GBM and compared it with conventional 2D cultures with respect to their response to radiation and to molecular targeted agents for which clinical data are available. Results: In 3 patient-derived GBM lines, no difference in radiation sensitivity was observed between 2D and 3D cultures, as measured by clonogenic survival. Three different molecular targeted agents, for which robust clinical data are available were evaluated in 2D and 3D conditions: (i) temozolomide, which improves overall survival and is standard of care for GBM, exhibited statistically significant effects on clonogenic survival in both patient-derived cell lines when evaluated in the 3D model compared with only one cell line in 2D cells; (ii) bevacizumab, which has been shown to increase progression-free survival when added to standard chemoradiation in phase III clinical trials, exhibited marked radiosensitizing activity in our 3D model but had no effect on 2D cells; and (iii) erlotinib, which had no efficacy in clinical trials, displayed no activity in our 3D GBM model, but radiosensitized 2D cells. Conclusions: Our 3D model reliably predicted clinical efficacy, strongly supporting its clinical relevance and potential value in preclinical evaluation of drug-radiation combinations for GBM.

ORCID iDs

Gomez-Roman, Natividad ORCID logoORCID: https://orcid.org/0000-0002-2325-7517, Stevenson, Katrina, Gilmour, Lesley, Hamilton, Graham and Chalmers, Anthony J;
CORE (COnnecting REpositories)